CDK6 and endometrial cancer: Taken together, these results indicate that (1) palbociclib is capable of inducing dephosphorylation of NPM/B23 at the Thr199 site and (2) CDK6 is involved in the phosphorylation of NPM/B23 in endometrial cancer.